Description
Verigat 5 mg is a prescription medication containing Vericiguat, a soluble guanylate cyclase (sGC) stimulator. It is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Manufactured by The ACME Laboratories Ltd. in Bangladesh, Verigat 5 mg is available in tablet form. The recommended starting dose is 2.5 mg orally once daily with food, doubling the dose approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.
.jpeg)
.jpeg)
.png)
.png)
.webp)
.webp)
.webp)
.png)
.jpeg)
Change Language